Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus Bevacizumab in Metastatic Melanoma
NCT00591734Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jan 2008
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in melanoma, sponsored by SCRI Development Innovations. Primary endpoint: Progression-free Survival at 13 months. Started Jan 2008; status: completed.
02
Drugs
everolimus
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00591734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00591734.